Navigation Links
Tepha Partner Launches Novel Monofilament Absorbable Suture Utilizing Tepha's Proprietary Biomaterial
Date:5/1/2009

Tepha Corporate Partner, Aesculap AG, Introduces MonoMax(R) Monofilament Suture at the German Surgical Congress in Munich following Receipt of CE Mark

LEXINGTON, Mass., May 1 /PRNewswire/ -- Tepha, Inc., a developer of medical devices announced today that its corporate partner, Aesculap AG, has received a CE Mark and is launching its MonoMax monofilament absorbable suture for general surgical indications in Europe. The product is made with TephaFLEX(R) fiber, one of Tepha's new class of novel resorbable polyhydroxyalkanoate (PHA) polymers. The Tepha PHA polymer family is a product of the Company's patented recombinant DNA technology, which allows the engineering of resorbable medical devices with mechanical and biologic properties that are matched to specific tissue repair and replacement applications. MonoMax monofilament suture has longer strength retention than currently marketed resorbable sutures, and is more flexible. The product joins a strong portfolio of suture products from B. Braun Aesculap, currently at number two in share of the European suture market.

Miguel Pablo, Vice President Marketing & Sales and Regulatory Affairs Closure Technologies for the Aesculap Division stated, "B. Braun Aesculap is excited to be introducing this new technology into the European market for wound closure. We have been working with Tepha for several years to develop the MonoMax product line and believe Tepha's unique biomaterial will provide benefits to our customers and to their patients".

A clinical trial, the Multi-Center Study to Evaluate the Safety and Efficacy of Aesculap MonoMax for Abdominal Wall Closure or (ISSAAC), was recently concluded with positive results. The trial enrolled approximately 150 patients who were followed for twelve months after surgery. In the trial, the MonoMax suture was used for a continuous all-layer (except skin) suture to close abdominal wall after midline incision
'/>"/>

SOURCE Tepha, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Dr Stephan Rietiker Joins BioCeramic Therapeutics
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
5. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
6. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
7. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
8. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
9. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
10. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
11. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... The Scientist, a leading scientific ...etrics’ Evolve “Intelligent” EMC...quo;Top 10 Innovations of 2009. , ...trade; EMCCD camera from Photometrics ®, a d...nd EMCCD cameras for the life sciences, was ranked...
(Date:12/1/2009)... Dr. Kerry Solomon announced that he ...nched his redesigned website at www.DrKerrySolomo...Group. Dr. Solomon is a proven LASIK, lens implan...sionally recognized for his substantial contributi... a member of Trusted LASIK Surgeons, which screens...
(Date:12/1/2009)... , NEW YORK, Dec. 1 Reportlinke...is available in its catalogue: ,, Chromium - ...ker.com/p0164494/Chromium---Global-Market-Trends.h...ily influenced by stainless steel, while growth in...lso important for growth of chromium metal. Enviro...
(Date:12/1/2009)... , NEW YORK, Dec. 1 Reportlinke...is available in its catalogue: ,, Emerging Cli...amics and the changing healthcare and regulatory e...65658/Emerging-Clinical-Trial-Locations---Eastern-...-and-regulatory-environment.html ,, Over the l...
Breaking Biology Technology:The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8
...., Feb. 3 Genomic Health,Inc. (Nasdaq: GHDX ) t...ess for,the fourth quarter and year ended December...ter of 2008 increased to $31.2 million,compared wi...roduct revenue,from the Oncotype DX(R) breast canc...f 2008, an increase of 60 percent, compared with $...
...Newswire-FirstCall/ - Victhom Human Bionics Inc., ...obionix division has obtained CE Mark approval for... for a closed-loop system (CLS) used on peripheral...eded for the sale of the Neurostep(TM) in any of t...ostep(TM), a fully implantable investigational neu...
...hite Paper Reports More Than 75% of Biotech Firms ...ship in Next Three Years , , NEW YORK, Feb. 3 Mo...plore business partnerships and strategic alliance...ding to "Plumbing the Depths," a new white paper r... www.rkco.com ). Results were based on the finding...
Other Biology Technology:Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 2Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 4Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 5Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 6Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 7Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 8Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 9Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 2Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 3Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass 2Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass 3Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass 4
(Date:12/3/2009)...LADELPHIA Now in its 32nd year, the CTRC-AACR San...act the best in breast cancer science and world le...eradicating breast cancer. , This year, more th...ather at the Henry B. Gonzales Convention Center i...is a partnership between the American Association ...
(Date:12/3/2009)...est dwellers must be included in the design of the...oid a humanitarian crisis, according to a scientis...n Nature , Dr Simon Lewis argues that at least 50...penhagen, known as REDD (Reducing Emissions from D...orest dwellers directly, and their property rights...
(Date:12/2/2009)...HILADELPHIA Children exposed to secondhand cigare...g cancer in adulthood, even if they never smoked. ...r Epidemiology, Biomarkers & Prevention , a journa... as part of a special tobacco focus in the Decembe...mericans will be diagnosed with lung cancer; more ...
Breaking Biology News(10 mins):CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Over 60 Firms Confirmed to Attend CBIs Third Annual Bio Pharmaceutical Collaboration and Transaction Accounting Conference in September 13715 1Over 60 Firms Confirmed to Attend CBIs Third Annual Bio Pharmaceutical Collaboration and Transaction Accounting Conference in September 13715 2Memorial Blood Centers in Urgent Need of Type O Negative and Type B Negative Blood Donors 55487 1Memorial Blood Centers in Urgent Need of Type O Negative and Type B Negative Blood Donors 55487 2ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 1ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 2ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 3
...nstitute have discovered that a protein known as F...rts of the body may have a function in the regulat...cate tissues that cannot survive the "inflammation...hat this discovery may ultimately help in the deve...h as macular degeneration and autoimmune diseases ...
... Department of Energy,s Pacific Northwest National...e machinery of life -- bringing us one step closer...he environment and protecting the country against ...ed "sequence alignment tool" that can divide the w...ragments so large data sets can run on many proces...
...ity genes by screening the genome of Caenorhabditi...ganism in genetics studies. The findings are repor...h of the 23 genes somehow normally acts to reduce ...eases lifespan. For example, the worm,s lifespan d...operly, and inhibition of another gene increases t...
Other Biology News:A protein in the eye may prevent immune response and protect eyes from disease 2Genomic sequences processed in minutes, rather than weeks 2
GR4 Auto Access 100V/50-60Hz from Thermo Scientific
...UF040A is a diluent that is designed for use with ...ies which are paired with a mouse monoclonal coati...d mouse proteins to prevent non-specific binding b...ll; This buffer may be used to stabilize newly c...
EZ-Tn5 Transposase from EPICENTRE Biotechnologies
...BL's bioassays for interferons are cytopathic effe...ral assays. Sample types include; tissue culture ...ormulations. In these assays, one unit is defined...iter to reduce the cytopathic effect of viral infe...
Biology Products: